The superiority of neoadjuvant chemotherapy over adjuvant chemotherapy in pancreatic
ductal adenocarcinoma survival remains to be determined.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics, 2016.CA Cancer J Clin. 2016; 66: 7-30
- Recent trends in survival of patients with pancreatic cancer in Germany and the United States.Pancreas. 2016; 45: 908-914
- Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.Cancer Res. 2014; 74: 2913-2921
- 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience.J Gastrointest Surg. 2006; 10 ([discussion: 1210–1]): 1199-1210
- Resection margins in pancreatic cancer: are we entering a new era?.HPB (Oxford). 2014; 16: 1-2
- Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicenter prospective evaluation of resection margins in 150 evaluable specimens.HPB (Oxford). 2013; 16: 20-33
- Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.Ann Surg Oncol. 2013; 20: 2787-2795
- Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas.J Gastrointest Surg. 2001; 5: 27-35
- Pancreatic adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network. 2017; 15: 1028-1061
- Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.Ann Surg Oncol. 2006; 13: 1035-1046
- Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.Ann Surg Oncol. 2009; 16: 1751-1756
- Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101.JAMA Surg. 2016; 151: e161137
- International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.Pancreatology. 2018; 18: 2-11
Washington K. Protocol for the Examination of Specimens from Patients with Carcinoma of the Exocrine Pancreas. Guidelines of the College of American Pathologists. 2015.
- Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1,399 patients.Ann Surg. 2014; 260: 494-503
- Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.JAMA. 2007; 297: 267-277
- Comparison of adjuvant gemcitine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicenter, open-label, randomized, phase 3 trial.Lancet. 2017; 389: 1011-1024
- FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.N Engl J Med. 2018; 379: 2395-2406
- FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med. 2011; 364: 1817-1825
- Locally advanced pancreatic cancer: neoadjuvant therapy with FOLFIRINOX results in resectability in 60% of the patients.Ann Surg. 2016; 264: 457-463
- Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.Ann Surg. 2015; 262: 12-17
- Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.Ann Surg. 2001; 234: 758-768
- Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer.Ann Surg. 2012; 255: 103-108
- Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines.Pancreas. 2013; 42: 1004-1010
- Preoperative radiochemotherapy versus surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1).J Clin Oncol. 2018; 36
- Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic cancer.Ann Surg. 2019; 270: 400-413
- Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients.Ann Surg. 2003; 237: 74-85
- 2564 resected periampullary adenocarcinomas at a single institution: trend over three decades.HPB (Oxford). 2014; 16: 83-90
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.Lancet Oncol. 2016; 18: 543-548
- A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer.J Gastrointest Surg. 2011; 15: 2059-2069
- Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis.J Clin Oncol. 2017; 35: 515-522
- FOLFIRINOX versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma.Ann Surg Oncol. 2018; 25: 1896-1903
- A multi-institutional phase II trial of preoperative full dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma.Ann Surg Oncol. 2006; 13: 150-158
- Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: new neoadjuvant regimen was safe and provided an interesting pathologic response.Eur J Surg Oncol. 2010; 36: 987-992
- Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.Cancer. 2012; 11891: 268-277
- Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.Ann Surg Oncol. 2013; 20: 3787-3793
- A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.Cancer. 2013; 119: 2692-2700
- Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.Am J Surg. 2008; 195: 318-321
- The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings.Semin Oncol. 2015; 42: 144-162
- Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin negative and node negative rates at resection.J Dig Surg. 2017; 18: 642-649
- Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.J Clin Oncol. 2008; 26: 3487-3495
- Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.J Clin Oncol. 2008; 26: 3496-3502
- Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.J Surg Oncol. 2010; 101: 587-592
- Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study.BMC Cancer. 2014; 14: 411
- Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.BMC Cancer. 2017; 17: 505
- Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.J Am Coll Surg. 2008; 206: 833-846
- Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.Int J Radiat Oncol Biol Phys. 2013; 86: 516-522
- Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.Radiother Oncol. 2014; 113: 41-46
- Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base.Cancer. 2014; 120: 499-505
- Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.PLoS Med. 2010; 7: e1000267
- Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer?.Ann Surg. 2018; 268: 1-8
- Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma.JAMA Surg. 2017; 152: 1048-1056
- Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.Ann Surg Oncol. 2014; 21: 1530-1537
- ISRCTN8950. ESPAC-5F: European Study Group for Pancreatic Cancer—Trial 5F.(Available at:) (Accessed February 9, 2019)
- SWOG S1505: a randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adernocacinoma.J Clin Oncol. 2018; 36
- Pancreaticoduodenectomy and vascular resection: persistent controversy and current recommendations.Ann Surg Oncol. 2009; 16: 789-791
- Regional resection of cancer of the pancreas: a new surgical approach.Surgery. 1973; 73: 307-320
- Technical risk factors for portal vein reconstruction thrombosis in pancreatic resection.J Vasc Surg. 2015; 62: 424-433
- Techniques and results of portal vein/superior mesenteric vein reconstruction using femoral and saphenous vein during pancreaticoduodenectomy.J Vasc Surg. 2010; 51: 662-666
- Pancreaticoduodenectomy with vascular resection: margin status and survival duration.J Gastrointest Surg. 2004; 8: 935-949
- Patency rates of portal vein/superior mesenteric vein reconstruction after pancreatectomy for pancreatic cancer.J Gastrointest Surg. 2014; 18: 2016-2025
- Arterial resection at the time of pancreatectomy for cancer.Surgery. 2014; 155: 919-926
- Organoid profiling identifies common responders to chemotherapy in pancreatic cancer.Cancer Discov. 2018; 8: 1112-1129
- Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial.Clin Cancer Res. 2018; 24: 1344-1354
- Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX.Ann Surg. 2019; 269: 733-740
- Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer.Ann Surg. 2019; https://doi.org/10.1097/SLA.0000000000003284
- Perioperative and survival outcomes following neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in patients with pancreatic adenocarcinoma.JOP. 2018; 19: 75-85
- Association of modified-FOLFIRINOX-regimen-based neoadjuvant therapy with outcomes of locally advanced pancreatic cancer in Chinese population.Oncologist. 2019; 24: 301.e93
- Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience.Ann Surg. 2019; https://doi.org/10.1097/SLA.0000000000003301
- Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis.Eur J Surg Oncol. 2018; 44: 1619-1623
Article info
Publication history
Published online: June 24, 2020
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
